Elemer Piros

The American Society of Hematology (ASH) held its annual December meeting in San Diego, where some of the biggest biotech companies announced clinical trial results, new drug updates and future initiatives. In separate reports, Cantor Fitzgerald analysts mentioned their takes on the announcements...

Cantor Fitzgerald has raised its price target on GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) to $208/ADS from $182/ADS after additional positive Epidiolex results. Epidiolex Significance The recent data of Epidiolex presented at the American Epilepsy Society (AES) event showed “robustness and...

Cannabinoid drug developer GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is ending an eventful 2016 on a high note. Shares were surging higher by 6.6 percent on Monday following new drug data out over the weekend and a strong fiscal Q4 earnings report out Monday. Over the weekend, the company reported...

Over the weekend, GW Pharmaceuticals PLC – ADR (NASDAQ: GWPH) presented additional data from its Phase III trials of Epidiolex in Lennox-Gastaut (LGS) and Dravet syndromes, at the American Epilepsy Society (AES) meeting. Cantor Fitzgerald’s Elemer Piros maintained a Buy rating on...

Bluebird bio Inc (NASDAQ: BLUE) announced positive early data from its ongoing open-label Phase 1 CRB-401 study with its CAR T candidate, bb2121, in patients with relapsed and/or refractory multiple myeloma. Although the initial early data is encouraging, there are potential risk of CRS [...

An article on TheStreet.com reiterated a bear thesis for Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP), while quoting a source saying the phase II clinical trial data of resunab were “nowhere near as robust or convincing as the company claimed them to be.” Cantor Fitzgerald’...

Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) announced positive results for the Phase 2 study of Resunab for diffuse cutaneous systemic sclerosis. Cantor Fitzgerald’s Elemer Piros reiterated a Buy rating on the company, with a price target of $17. Positive Data “Resunab achieves...

While most eyes were on the election on Tuesday evening, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) provided an update on their Heparc-2004 clinical study of ARC-520. In an 8:05 p.m. press release, the company announced the study was verbally put on hold by the FDA following deaths in non-human...

Shares of Abeona Therapeutics Inc (NASDAQ: ABEO) were trading higher by more than 11 percent Thursday after the company reported initial data from a 30-day study involving three Sanfillipo Type A patients treated with the company's therapy candidate ABO-102 at low doses (5E12vg/kg)....

Omeros Corporation (NASDAQ: OMER) reported positive initial results for its Phase 2 trial of OMS721, a complement inhibitor for renal diseases. Cantor Fitzgerald’s Elemer Piros reiterated a Buy rating on the company, with a price target of $21. Effective Candidate “In two out of the...

Cantor Fitzgerald wasn’t impressed by bluebird bio inc (NASDAQ: BLUE)’s investor day event on Thursday. Analyst Elemer Piros downgraded the stock to Sell following the event and doesn’t expect any new data from the company at the upcoming ASH conference in December. According...

Cantor Fitzgerald analysts see Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) achieving three clinical inflection points during the next 12 months. The firm started coverage of the stock with a Buy rating and price target of $17, implying a potential upside of 142 percent. Catalysts In Pipeline...

Shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) climbed as much as 15 percent to $8.09 after it announced a joint collaboration with Amgen, Inc. (NASDAQ: AMGN) to advance two of its cardiovascular (CV) RNAi programs. Amgen will pay Arrowhead $35 million upfront, invest $21.5 million in...

Shares of GW Pharmaceuticals PLC (NASDAQ: GWPH) were trading higher by more than 17 percent Monday, but analysts at Cantor Fitzgerald believe the surge has just begun. GW Pharma announced a second successful pivotal trial in an ongoing Phase 3 trial which explores Epidiolex, its lead...